Table 3.
Analysis of CNS Toxicity in CYP2C19 Subgroups in Patients with Voriconazole
| Neurotoxicity n (%) | Non-Neurotoxicity n (%) | Cmin (mg/L) | Cmin/DMD | |
|---|---|---|---|---|
| Gene states | ||||
| UM | 0 | 1 (1.0%) | 2.69 | 0.027 |
| EM | 12 (46.2%) | 35 (36.5%) | 4.78±2.84 | 0.029±0.017 |
| IM | 9 (34.6%) | 43 (44.8%) | 4.71±2.32 | 0.030±0.016 |
| PM | 5 (19.2%) | 17 (17.7%) | 4.80±2.73 | 0.034±0.022 |
Abbreviations: Cmin/DMD, the ratio between the voriconazole Cmin at steady state and the maintenance dose; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.